Loading stock data…
Genprex (GNPX)
$3.54+0.04 (+1.14%)
Market ClosedLast close Sep 8
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Genprex, Inc. in the Healthcare sector is trading at $3.54 with a market capitalization of $5M. The stock is currently near its 52-week low of $3.37, remaining 88.4% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 31) — potential for technical mean-reversion
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$4.49M↓ | -$3.52M↓ | -$3.35M↑ | -$4.68M↓ | -$3.97M |
| Net Income | -$4.46M↓ | -$3.79M↑ | -$3.80M↑ | -$4.67M↓ | -$3.96M |
Peer Comparison
JNJUNHPFE
Fundamentals
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$4.94M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-98.79%
Volume
Today's trading volume
28,520
Recent News
Genprex Shares Rise After Collaboration With Roche Diagnostics
Genprex Inc. (NASDAQ:GNPX) shares gained 3% on Monday after the clinical-stage biotechnology company announced a collaboration with Roche Diagnostics to validate biomarkers designed to improve patient selection in clinical trials for non-small cell lung cancer (NSCLC).
Genprex’s Reqorsa combo secures Canadian patent for lung cancer
Reqorsa is currently in development alongside approved cancer drugs.